RDM1 is reported to be involved in the cell response to cisplatin (Hamimes et al., 2005) and acts as an oncogene in several cancers; however, loss of RDM1 could promote liver cancer progression by the Ras/Raf/ERK and p53 pathways (Chen et al., 2020). This evidence concerns the gene TP53 and liver cancer.